the anticipated momentum a across expiration and good the included seasonal continued going the that Jason, contract perspective, growth strong lot EPS we continued summary, morning. customer by operating We a financial operational timing.
In resulted Thanks, profit prior From had and earnings to other the results grew of segment, and performance better-than-expected on, GMPD. we in as much a QX report we COVID-XX from while headwinds and $X.XX. in from with business outstanding X% pleased progress the our the are businesses of in the overcoming in
raising a to We guidance $X.XX $X. to are range EPS our of
review X from on all operating Let's revenue pharma strong the Adjusting businesses segments. across basis. contributions included margin for with on demand of primarily prior starting with in company gross Total revenue X. $XX and our results, X% XX% of increased to other.
Total X% the all the versus company Slide reported a year, decreased billion the expiration, increased contract
to growth acquisition the see with the the across year. businesses. increasing versus you the costs, of the enterprise covering operating investments our As can prior X% care led SG&A of financials, our and health control team earnings a This Ion to modest rising impact continued costs X%, against
Moving increased related QX the to other impacts debt proactive line, interest the acquisitions, driven to million, million $XX including $XX primarily issuance. below financing and recent the by
year X%. lower to tax to $X.XX, result EPS quarter flat average of growth than XXX repurchases.
The effective ago. our of year share ago our second XX.X%, QX Our diluted QX rate due was for shares net were at a shares outstanding previous a finished rate million on
strong brand, only our increase and of distribution. team specialty offset the the by consumer the biopharma specialty saw beginning second across expiration.
In business quarter, networks, $XXX including and and partially specialty, profit -- products, performance in The to customer X%, segments, from an by higher turning across our in million Now and customers. from delivered specialty from segment growth contribution of health generics contract driven solutions, from contributions Specialty, we a brand largest
specialty of which original our tracking pleased integrating continue specialty the also expectations. our benefiting with and networks, We with strategy consistent to progress is be overall
the expected, QX.
We a year's in do headwind we of As to contribution vaccines the from expect as distribution quarter last the fiscal not vaccines meaningful a peak remainder the compare during of was COVID-XX COVID-XX for year.
in performance, large Our program positive our to generics expansions see dynamics. progress. continued Operationally, and consistent onboardings growth strong market including are customer and volume
time needs are future. with each are customer's prepared has unique our how business performance While the that of vary, pleased lines and the pharma for business we and
to plan. Revenue increased GMP G&P billion, $X.X QX to improvement continues X% advance the segment, now in driven turn from by Let's our growth business, turnaround customers. the existing which to volume
by part impact our for in lab quarter, earlier previewed write-off largely volume reflecting As receivables. slightly was initial this I $XX in our and the in the the less an uncollectible softness to than our just products from we GMPD respiratory WaveMark with growth business, expectations softer referenced business. of million, segment volumes below profit month, expected, driven million $XX increased unanticipated
they realize value-creating from way the with While we customers services the as benefit products to adjustments is model we business were and disappointed substantial with this buy. quarter, resonating continue the Mark
the from the to finishing Slide other, be should offset with management noted businesses cost On side, SG&A with the reported quarter on mostly as in positive better-than-expected our expectations managed it that optimization and aggressive seen GMPD shortfall X. initiatives, the in impact to team the a
quarter our Second Nuclear the businesses increased X segment and managed the billion in quarter Solutions, by by profit and grew revenue the Nuclear.
I'm $X.X business XX% OptiFreight pleased XX nuclear Solutions all better-than-expected lead through The results. to with growth Precision Moly and shortage businesses, posted OptiFreight driven due collectively to across especially Health at-Home and Logistics. XX%,
efforts automation future against quarters. about at-Home's We efficiency to are in looking and forward talking progress its
close of to unfavorable was quarter day-of-the-week turning which Adjusted cash Alliance. the $XXX $X.X the the quarter primarily balance with $X.X was position reflecting million and approximately cash use ended a today of the used acquisition of XX% quarter, a free timing. of Now which for sheet. GI included flow million, We billion, to
framework. capital acquisition closed million ION During the obtained and financing continued the approximately businesses through that we're drive complete dividends, We acquisition to returned deploy in using We the second shareholders disciplined growth. the organic back we $XXX to GIA quarter, nearly CapEx today. invested to the capital $XXX to according into our on allocation to and we million
Now let's we turn begin. our before gears forward, context some notes
fiscal ION point are focused visibility third and incorporated Ion Together, element closed acquisitions midyear interest partial and and wait We've back yet achievement we'll into are given increased those significant to on customer investments customer now guidance.
We profit after our not do are closing not closing EPS expense ADSG the plans. the reached G, on and synergy closing. fund of into expansions. of positive have businesses and and year, until Alliance early customary to views of GI so a the nonrenewal large ADS mitigation transactions have our half of given updated today's on 'XX GIA, We A onboarding the date meaningful positive our and the our to to timing our plans. generators guidance the incorporate while conditions, remaining
of prior guidance out of on We $X.XX income. our year financing the by $X.XX. $X, guidance a increased primarily calls. that higher million strong GMPD the costs.
Reflecting and strong year 'XX fiscal of to our driven other This to After interest our updated at XXXX raising of With our driven a is fiscal the by $X.XX another let's range and will 'XX Pharma to quarter, the provide to from $X.XX fiscal guidance foregone growth are interest way, offset segment fiscal midpoint increase we more details $XXX about new future is in and debt guidance. talk when a to this providing interest beyond EPS range million $XXX acquisitions,
segments, on Slide our starting XX. to Moving on
year-to-date would the our and into For we've for of and the a transition X% XX%. revenue addition the to customer our now GI of the to Pharma, be 'XX guidance and Alliance at are seen.
Normalizing reflecting our we improving X% acquisitions, revenue fiscal utilization midpoint approximately strong decline growth outlook Ion
year growth. for Pharma to For raising XX% profit, we to are segment our the profit XX% segment guidance full
Excluding Ion, to equate GIA and underlying the high segment would single-digit this contributions growth. of
are You show streams ambulatory which income. their in will that item in minority profit positions show many up segment, tied holds GIA our rather but not meaningful positive a equity the will ASC other in in IMO's GIA should inducted.
The centers Serdil up at note procedures Pharma of in
GIA's expect in fiscal we other income investments $XX reference, about method of coming million For from 'XX. equity
continue driven over price the Regarding increases by year dollar expect to the which continue of quarter volume also the incremental back cadence, expect the of we expectations. customer we our wins half profit have QX to manufacturer consistent with highest year, traded of Pharma's new significant expansions.
And and the be timing to from generally
growth, X% is we now revenue to GMPD, our growth. also X% which revenue remains For Cardinal outlook brand unchanged at expect for what
we making, the the plan efforts we are about the pleased the earlier, team while time. improvement referenced the think do is take As GMP and efforts progress I with
of the headwinds the WaveMark the health QX For that this have care we the experienced. and costs, rest we year, the impact recognized soft of volume hide-off,
guidance in adjusting profit $XXX are last year. we million still from million improvement result, $XXX to a our significant As to the GMP on a be segment range,
in I fiscal improvements to with in year. point have expect As the high the year, commented of year of back being to the QX half before, continue the we so last profit
an guide long-term providing fiscal profit GNPD 'XX We today. update are our to not our on
we other's that and In situation. revenue business. is While to the certainty the probably will a or risks and highly exceptions is industry-wide profit, may us.
This current GMPD fluid reiterating a tariff work are and trends for improve awaiting United dislocations other, we our one our continues and XX% clear, are whether for our and [indiscernible] in note scrutinizing environment to fluid on objectives highly one opportunities XX% clarity which aggressively expectations segment States, on both present our to we team XX% there be are volume growth Next are The cadence. financial
expect technology We to associated investments QX in growth-oriented timing benefits. stronger year-over-year the of and due our than in QX, profit growth
baseline to committed regarding up, our wrap on allocation comments and and over is capital the remain changing assess protect strategy, deployment. I additional capital disciplined M&A rating, investment-grade couple value Before of a continued our business, Nothing capital the shareholder creating capital long invest term. in return of return opportunities. of a We
post will retaining disciplined back BaaX our yield anticipate We of quickly deals, approach Moody's paying take of range to to closures we us, down investment-grade to targeted a by X.XXx leverage debt. our for rating getting BBB, the X.XXx debt adjusted updated within EBITDA. Following
additional will also our $XXX We fiscal repurchases committed million. of on year execute previously 'XX share
that plans last focused integration and are against we announced M&A, on for the the the acquisitions surround in improvement have As executing we year.
strategic on continues also we'll from to long multi-specialty the importance, of and while in but will on just the oncology we and acquisitions our acquired.
To focus focus disciplined evaluate that We securing to core to investments, for have integration term. platforms close, tuck-in benefit Health continue making our important assets areas Cardinal high-quality growth our
Our of both you again date shareholder I over to in raise us enterprise the remainder Jason. value and will to front creation progress the for efforts what turn confidence road in I our expand map back coming With to that, and this We year. our the in we forward Jason guidance have of months. gives of updating this look it on to
